SCHEMBL16013610

SCHEMBL16013610

O=c1[nH]c2ccc(Nc3ncnc4scnc34)cc2s1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
▸ MKNK1 Q9BUB5 15/20 1.00
▸ KIF11 P52732 1/20 0.44
▸ SYK P43405 1/20 0.43
▸ RIPK2 O43353 3/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15618645 0.80 MKNK1 (0.66) MKNK1KIF11SYK
SCHEMBL16013526 0.79 MKNK1 (1.00) MKNK1
SCHEMBL16013831 0.78 MKNK1 (0.66) MKNK1KIF11SYK
SCHEMBL16013307 0.77 MKNK1 (0.64) MKNK1SYK
SCHEMBL16013306 0.76 MKNK1 (1.00) MKNK1SYK
SCHEMBL16013055 0.76 MKNK1 (1.00) MKNK1
SCHEMBL16013395 0.76 MKNK1 (1.00) MKNK1
SCHEMBL16013830 0.76 MKNK1 (1.00) MKNK1SYK
SCHEMBL16013828 0.75 MKNK1 (0.72) MKNK1SYK
SCHEMBL16014470 0.75 MKNK1 (1.00) MKNK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9675612-B2 Substituted thiazolopyrimidines BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2017-06-13 — — US claimed
US-20160009734-A1 SUBSTITUTED THIAZOLOPYRIMIDINES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2016-01-14 — — US claimed
EP-2964656-A1 SUBSTITUTED THIAZOLOPYRIMIDINES Bayer Pharma Aktiengesellschaft (DE) 2016-01-13 — — EP claimed
WO-2014135480-A1 SUBSTITUTED THIAZOLOPYRIMIDINES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2014-09-12 — — WO claimed
US-9675612-B2 Substituted thiazolopyrimidines BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2017-06-13 — — US disclosed
US-9675612-B2 Substituted thiazolopyrimidines BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2017-06-13 — — US disclosed
US-20160009734-A1 SUBSTITUTED THIAZOLOPYRIMIDINES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2016-01-14 — — US disclosed
US-20160009734-A1 SUBSTITUTED THIAZOLOPYRIMIDINES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2016-01-14 — — US disclosed
EP-2964656-A1 SUBSTITUTED THIAZOLOPYRIMIDINES Bayer Pharma Aktiengesellschaft (DE) 2016-01-13 — — EP disclosed
WO-2014135480-A1 SUBSTITUTED THIAZOLOPYRIMIDINES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2014-09-12 — — WO disclosed
WO-2014135480-A1 SUBSTITUTED THIAZOLOPYRIMIDINES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2014-09-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160009734-A1 SUBSTITUTED THIAZOLOPYRIMIDINES DPYD, TYMP, THPO MKNK1 3409/4885KIF11 2567/4885SYK 1048/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback